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Abstract 
Background: In animal models for acute liver injury, the administration of some 
angiogenic factors such as vascular endothelial growth factor (VEGF) and 
granulocyte-colony stimulating factor (G-CSF) are shown to reduce liver injury and 
improve liver proliferative capacity. 
Aim: To assess the role of angiogenic factors in fulminant hepatic failure (FHF). 
Methods: Serum levels of nine angiogenic factors {angiopoietin-2, follistatin, G-CSF, 
hepatocyte growth factor (HGF), interleukin-8, leptin, platelet-derived growth factor 
(PDGF)-BB, platelet endothelial cell adhesion molecule-1 and VEGF} were measured 
using the Bio-Plex Protein Array System in 30 patients, 17 of whom were diagnosed 
with FHF and 13 with acute hepatitis (AH), and 20 controls. 
Results: Serum levels of PDGF-BB and VEGF were lower in FHF patients than AH 
patients and controls (PDGF-BB; 2050 ± 1572 pg/ml vs. 4521 ± 2419 pg/ml vs. 8506 ± 
5500 pg/ml, VEGF; 39 ± 38 pg/ml vs. 144 ± 122 pg/ml vs. 205 ± 121 pg/ml). By using 
univariate logistic regression models, serum levels of PDGF-BB and VEGF were 
associated with poor outcomes. Serum PDGF-BB levels were strongly correlated with 
serum VEGF levels (r = 0.70). Furthermore, serum PDGF-BB levels were significantly 
correlated with platelet counts (r = 0.79), PT activity (r = 0.37) and D.Bil/T.Bil ratio (r = 
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0.50), while serum VEGF levels were significantly correlated with platelet counts (r = 
0.68) and PT activity (r = 0.38). 
Conclusions: Serum levels of PDGF-BB and VEGF are worth investigating as 
biomarkers for predicting outcomes of FHF patients. 
 
Key Words: fulminant hepatic failure, platelet-derived growth factor–BB, vascular 
endothelial growth factor, hepatocyte growth factor, prognostic factor. 
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Introduction 
Fulminant hepatic failure (FHF) is caused by liver cell death of a critical degree 
and characterized by hepatic encephalopathy and coagulopathy. The spontaneous 
survival rate was reported 60-70% in acetaminophen-related FHF and 20-40% in 
non-acetaminophen-related FHF.1-3 While, in FHF patients with fatal outcomes, post 
liver transplantation survival ranges between 60% and 80%,4 and liver transplantation is 
the most reliable treatment for FHF. 
The condition of FHF changes dramatically. If liver transplantation is performed 
too late, there is increased risk of multiple organ failure and infection. A recent report 
showed that, in a setting of donor organ shortage, a fourth of the patients listed for 
emergency liver transplantation were unable to undergo surgery.5 Thus, in addition to 
liver transplantation, new therapeutic modalities for promoting liver regeneration are 
desired.  
In a rat model for acute severe liver injury, the administration of vascular 
endothelial growth factor (VEGF) is reported to promote hepatocyte proliferation and 
reduce the mortality.6 Furthermore, in a rat model for FHF, granulocyte-colony 
stimulating factor (G-CSF) is shown to reduce liver injury and improve liver 
proliferative capacity.7 Thus, the administration of these angiogenic factors may be 
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effective treatment for FHF. 
Clinically, G-CSF administration is shown to induce proliferation of hepatic 
progenitors in patients with alcoholic steatohepatitis, which leads to liver regeneration.8 
However, the role of these angiogenic factors in FHF patients has been yet to be fully 
implemented. This study aimed to investigate the associations of serum levels of various 
angiogenic factors including VEGF and G-CSF with clinical characteristics and 
prognosis of FHF patients. 
 
Methods 
Patients 
The study-subjects consisted of 30 patients, 17 of whom were diagnosed with 
FHF and 13 with acute hepatitis (AH), and 20 healthy controls.  
Patients were diagnosed as FHF when hepatic encephalopathy of coma grade 
greater II developed within 8 weeks after the onset of disease symptoms with a 
prothrombin time less than 40% of the standardized values (Japanese diagnostic 
criteria).2 However, those who’s computed tomography showed the features of chronic 
liver disease (splenomegaly or varices, collaterals) were excluded. 
Etiology of FHF 
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A diagnosis of fulminant hepatitis A, B and C was made based on the presence of 
immunoglobulin M antibody to hepatitis A virus, immunoglobulin M antibody to 
hepatitis B core antigen or hepatitis B surface antigen, and hepatitis C virus RNA 
identifiable by nested reverse transcription-polymerase chain reaction, respectively.9 A 
diagnosis of autoimmune hepatitis was made according to the criteria revised by the 
International Autoimmune Hepatitis Group in 1999.10 A diagnosis of Epstein-Barr virus 
infection was made based on measurement of Epstein-Barr virus load in whole blood by 
quantitative polymerase chain reaction amplification assays.11 A diagnosis of 
drug-induced liver injury, acute fatty liver of pregnancy and ischemic hepatitis was 
made based on their distinctive clinical courses. A diagnosis of indeterminate FHF was 
established when all of IgM anti-hepatitis A virus antibody, IgM anti-hepatitis B virus 
core antibody, hepatitis B surface antigen, hepatitis C virus-RNA, anti-nuclear antibody 
and anti-smooth muscle antibody were negative with no obvious cause such as drug, 
acute fatty liver of pregnancy, ischemic hepatitis, Wilson’s disease, malignant 
infiltration, cytomegalovirus infection, Epstein-Barr virus infection and herpes simplex 
virus infection. 
Measurement of angiogenic markers concentration 
Serum was collected when patients were admitted to our hospital and before 
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treatment, and stored at -80°C.   
Serum levels of angiogenic factors were measured using the Bio-Plex Protein 
Array System with the Bio-Plex Pro Human Angiogenesis 9-Plex Panel (Bio-Rad 
Laboratories, Hercules, CA, USA). This panel consisted of angiopoietin-2, follistatin, 
G-CSF, hepatocyte growth factor (HGF), interleukin 8 (IL-8), leptin, platelet-derived 
growth factor (PDGF)-BB, platelet endothelial cell adhesion molecule (PECAM)-1 and 
VEGF. In brief, the Bio-Plex Pro Angiogenesis Standard and samples diluted in Serum 
Diluent were added to a 96 well filter plate and incubated with the antibody-coupled 
beads for 1 h with continuous shaking. The beads were washed three times with wash 
buffer to remove unbound protein and incubated with biotinylated detection antibodies 
for 30 min with continuous shaking. Following three washes, premixed 
streptavidin-phycoerythrin was added to each well and incubated for 30 minutes. After 
incubation, the beads were washed and re-suspended in assay buffer. The reaction 
mixture was quantified using the Bio-Plex protein array reader. Each angiogenic marker 
level was automatically calculated by Bio-Plex Manager software using the appropriate 
standard curve. 
Statistical Analysis 
SPSS statistical program (release 11.0.1 J, SPSS, Chicago, IL, USA) was used for 
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the statistical analysis. 
Dichotomous variables were compared by the Fisher's exact test. Continuous 
variables were expressed as mean ± standard deviation. The Mann–Whitney U test was 
used to evaluate differences in the continuous variables between two groups, and the 
Kruskal–Wallis test was carried out among three groups. The Spearman correlation 
coefficient was used to evaluate the consistency in the continuous variables between 
two groups. To identify the association of serum angiogenic factors with poor outcomes, 
we developed the univariate Cox proportional hazard models. The prognostic accuracy 
of each factor was evaluated based on the area under the curve (AUC) using receiver 
operating characteristic curve analysis. P-values <0.05 were considered significant. 
 
Results 
Characteristics on admission 
Of 17 FHF patients, 5 survived spontaneously, 6 patients received living donor 
liver transplantation, and the remaining 6 patients died without liver transplantation. All 
17 AH patients survived spontaneously. Table 1 shows clinical characteristics and 
laboratory data on admission of FHF patients and AH patients. Direct bilirubin/total 
bilirubin (D.Bil/T.Bil) ratio and prothrombin (PT) activity were lower in FHF patients 
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than AH patients. Age, gender, etiology and serum levels of T.Bil and transaminase 
were similar between FHF patients and AH patients.  
Serum levels of angiogenic factors 
Table 2 shows serum levels of 9 angiogenic factors on admission in FHF patinets, 
AH patients and controls. There were significant differences in serum levels of HGF, 
IL-8, PDGF-BB and VEGF among the 3 groups. Serum levels of PDGF-BB and VEGF 
were lower in FHF patients than AH patients and controls (FHF patients vs. AH 
patients: P = 0.002 and 0.004, respectively; FHF patients vs. controls: P = <0.0001 and 
0.0005, respectively). Serum IL-8 levels were lower in FHF patients than AH patients (P 
= 0.002); however there were no differences in serum IL-8 levels between FHF patients 
and controls (P = 0.19). Serum HGF levels were higher in FHF patients than controls (P 
= 0.0004), while differences in serum HGF levels between FHF patients and AH 
patients were borderline (P = 0.069). On the other hand, there were no differences in 
serum levels of angiopoietin-2, follistatin, G-CSF, leptin and PECAM-1 among the 3 
groups. 
Association of serum levels of angiogenic factors with prognosis  
In the 30 patients with FHF or AH, between 12 patients with good outcomes and 
18 patients with poor outcomes (including death and liver transplantation), there were 
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significant differences in serum levels of HGF (3037 ± 2313 pg/ml vs. 13014 ± 24635: 
P = 0.004), PDGF-BB (4099 ± 2413 pg/ml vs. 1653 ± 1072 pg/ml: P = 0.002) and 
VEGF (120 ± 114 pg/ml vs. 32 ± 25 pg/ml: P = 0.010) (Figure 1). By univariate logistic 
regression models, serum levels of PDGF-BB and VEGF were associated with poor 
outcomes in the 30 patients with FHF or AH (Table 3). The association of serum HGF 
levels with poor outcomes was borderline. There were no associations between serum 
levels of the other angiogenic factors and the prognosis. 
Table 4 shows the AUC of platelet count, D.Bil/T.Bil ratio, PT activity, and serum 
levels of HGF, PDGF-BB and VEGF as a prognostic factor. The AUC of PDGF-BB was 
equal to those of T.Bil/D.Bil ratio and PT activity. 
In the 30 patients with FHF or AH, serum PDGF-BB levels were significantly 
correlated with serum VEGF levels (r = 0.70, P <0.0001) (Table 5). Furthermore, serum 
PDGF-BB levels were correlated with platelet counts (r = 0.79, P <0.0001), PT 
activities (r = 0.37, P-value = 0.044) and D.Bil/T.Bil ratio (r = 0.50, P = 0.006). On the 
other hand, serum VEGF levels were correlated with platelet counts (r = 0.68, P 
<0.0001) and PT activities (r = 0.38, P = 0.040). 
 
Discussion 
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In a setting of donor organ shortage, it is important to accurately identify FHF 
patients with poor outcomes in order to rescue more patients with liver transplantation. 
However, biomarkers for predicting accurate prognosis fall short. Previously, serum 
copy number of transforming growth factor-alpha mRNA and serum HGF levels were 
reported as biomarkers for predicting the prognosis of FHF patients.12,13 However, the 
specificity (65.5%) of serum copy number of transforming growth factor-alpha mRNA 
was not sufficient in the original report.12 Furthermore, in this study, the association of 
serum HGF levels with the prognosis of patients with FHF or AH was borderline. So, 
another biomarker is required. This study suggests that serum levels of PDGF-BB and 
VEGF may be useful as biomarkers for predicting a poor prognosis of FHF patients. 
This report is the first concerning serum levels of PDGF-BB and VEGF in FHF patients 
although sample size of this study was limited. We consider that serum levels of 
PDGF-BB and VEGF are worth investigating as biomarkers for predicting outcomes of 
FHF patients. In order to confirm these findings, a further study with larger sample size 
is required. 
In this study, serum levels of PDGF-BB and VEGF were well correlated with 
platelet counts. Platelet release angiogenic factors such as PDGF-BB and VEGF.14,15  
In FHF patients, platelet counts and serum thrombopoietin levels are decreased.16 
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Thrombopoietin, produced primarily in the liver but also in the bone marrow and kidney, 
binds to the thrombopoietin receptor expressed on the surface of stem cells, 
megakaryocyte progenitor cells, megakaryocytes, and platelets.17 Thrombopoietin 
regulates the development and maturation of megakaryocytes and subsequent release of 
platelets. Additionally, thrombopoietin enhances platelet activation and function. Thus, 
we speculate that thrombocytopenia due to the decrease of serum thrombopoietin levels 
may lead to the decrease of serum PDGF-BB and VEGF levels. Furthermore, in this 
study, serum levels of PDGF-BB and VEGF were correlated with PT activities. So, 
serum levels of PDGF-BB and VEGF may reflect the extent of liver failure. 
In this study, the decrease of serum PDGF-BB and VEGF levels were associated 
with poor outcomes of FHF patients. Hepatocytes proliferation and liver regeneration 
are stimulated by VEGF.6,18 Furthermore, PDGF were reported to increase the 
expression of pleiotrophin, a potent mitogen for hepatocytes, in sinusoidal hepatic 
stellate cells.19 Thus, we speculate that the decrease of serum PDGF-BB and VEGF 
levels may delay liver regeneration, and this may result in the increased risk of multiple 
organ failure and infection and the poor outcomes in FHF patients. On the other hand, in 
human, clinical trials using recombinant VEGF or VEGF gene transfer were already 
reported.20,21 Treatment using PDGF-BB and VEGF may provide a new therapeutic 
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strategy for acute liver failure. 
Recently, a clinical trial of recombinant human HGF, which stimulates the 
proliferation of mature hepatocytes and hepatic progenitor cells, in patients with FHF 
was reported from Japan.22 In the study, 4 patients received the administration of 
recombinant HGF, of whom, 2 died due to progression of liver failure and 2 were 
rescued. However, from the first, serum HGF levels are higher in FHF patients than AH 
patients or healthy controls. On the other hand, this study indicates that serum levels of 
PDGF-BB and VEGF are lower in FHF patients. Thus, treatment using PDGF-BB and 
VEGF may be more reasonable. 
We consider that, in order to assess the usefulness of serum PDGF-BB and VEGF 
levels as biomarkers for predicting outcomes of FHF patients, the relation between the 
changes of serum PDGF-BB and VEGF levels during the clinical course and the 
prognosis of FHF patients should be assessed, although, in this study, we could not for 
lack of the serum collection after the introduction of treatment in AH patients and FHF 
patients. On the other hand, in this study, 13 of 17 FHF patients (76%) received plasma 
exchange combined with continuous hemodiafiltration. Serum IL-8 levels were reported 
to be decreased by plasma exchange combined with continuous hemodiafiltration.23 
However, the effect of plasma exchange combined with continuous hemodiafiltration on 
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serum PDGF-BB and VEGF levels has been yet to be fully implemented. Hereafter, to 
clarify these points is necessary. 
In conclusion, lower serum levels of PDGF-BB and VEGF were associated with 
poor prognosis of FHF patients in this study. Thus, we consider that serum levels of 
PDGF-BB and VEGF are worth investigating as biomarkers for predicting outcomes of 
FHF patients. 
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Table 1. Clinical characteristics and labolatory data on admission. 
 FHF AH P-value 
Patients, n 17 13  
Age, yr 37 ± 14 41 ± 17 0.34 
Gender, female (%) 12 (71%) 6 (46%) 0.26 
Etiology, n (%)    
 Viral hepatitis 5 (29%) 7 (54%) 0.26 
  HAV 1 (5%) 4 (31%)  
  HBV 4 (24%) 3 (23%)  
AIH 3 (18%) 3 (23%)  
Drug-induced 4 (24%) 1 (8%)  
 Indeterminate 5 (29%) 2 (15%)  
Period from initial symptoms to the diagnosis of fulminant hepatic failure, day 
 14 ± 12 — — 
Hepatic coma, n (%)    
 II 14 (82%) — — 
III or IV 3 (18%) — — 
Laboratory data    
 20
 WBC, /mm3 10829 ± 6698 7616 ± 2250 0.33 
 Hemoglobin, g/dl 13.2 ± 1.7 14.2 ± 2.2 0.18 
 Platelet, x104/mm3 12.0 ± 6.9 18.0 ± 8.3 0.054 
 T.Bil, mg/dl 14.3 ± 8.8 11.1 ± 8.15 0.27 
D.Bil/T.Bil ratio 0.59 ± 0.14 0.68 ± 0.03 0.027 
AST, IU/l 2876 ± 3888 2967 ± 4696 0.98 
 ALT, IU/l 2817 ± 2563 2728 ± 2573 0.93 
 Cr, mg/dl 1.0 ± 1.1 0.9 ± 0.5 0.45 
 PT activity, % 23 ± 10 42 ± 12 0.0005 
AH, acute hepatitis; AIH, autoimmune hepatitis; ALT, alanine aminotransferase; AST, 
aspartate aminotransaminase; Cr, creatinine; D.Bil, direct birilubin; FHF, fulminant 
hepatic failure; HAV, hepatitis A virus; HBV, hepatitis B virus; PT, prothrombin; T.Bil, 
total bilirubin; WBC, white blood cell. 
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Table 2. Serum levels of 9 angiogenic factors on admission. 
 FHF AH Control P-value 
Patients, n 17 13 20  
Angiopoietin-2, pg/ml 1078 ± 689 1440 ± 982 998 ± 462 0.51 
Follistatin, pg/ml 728 ± 752 1235 ± 1763 697 ± 207 0.11 
G-CSF, pg/ml 129 ± 57 260 ± 222 347 ± 335 0.22 
HGF, pg/ml 9958 ± 21015 3197 ± 2588 1981 ± 791 0.002 
IL-8, pg/ml 161 ± 68 710 ± 1167 263 ± 259 0.015 
Leptin, pg/ml 3441 ± 2774 3935 ± 2537 4530 ± 1728 0.15 
PDGF-BB, pg/ml 2050 ± 1572 4521 ± 2419 8506 ± 5500 <0.0001
PECAM-1, pg/ml 8340 ± 3347 6842 ± 3366 7573 ± 4328 0.47 
VEGF, pg/ml 39 ± 38 144 ± 122 205 ± 121 0.0005 
AH, acute hepatitis; FHF, fulminant hepatic failure; G-CSF, granulocyte 
colony-stimulating factor; HGF, hepatocyte growth factor; IL, interleukin; PDGF, 
platelet-derived growth factor; PECAM, platelet/endothelial cell adhesion molecule; 
VEGF, vascular endothelial growth factor. 
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Table 3.  Associations of serum levels of 9 angiogenic factors with poor outcomes in 
30 patients with FHF or AH by univariate logistic regression models. 
 Odds ratio 95% CI P-value 
Angiopoietin-2, per 1 pg/ml increase 1.00 0.99-1.00 0.78 
Follistatin, per 1 pg/ml increase 1.00 0.99-1.00 0.58 
G-CSF, per 1 pg/ml increase 0.99 0.98-1.00 0.15 
HGF, per 1 pg/ml increase 1.00 1.00-1.00 0.058 
IL-8, per 1 pg/ml increase 0.99 0.99-1.00 0.12 
Leptin, per 1 pg/ml increase 1.00 1.00-1.00 0.48 
PDGF-BB, per 1 pg/ml increase 0.99 0.99-1.00 0.012 
PECAM-1, per 1 pg/ml increase 1.00 1.00-1.00 0.17 
VEGF, per 1 pg/ml increase 0.97 0.95-0.99 0.045 
AH, acute hepatitis; CI, confidence interval; FHF, fulminant hepatic failure; G-CSF, 
granulocyte colony-stimulating factor; HGF, hepatocyte growth factor; IL, interleukin; 
PDGF, platelet-derived growth factor; PECAM, platelet/endothelial cell adhesion 
molecule; VEGF, vascular endothelial growth factor. 
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Table 4.  Prognostic accuracy by the AUC using receiver operating characteristic curve 
in 30 patients with FHF or AH. 
 AUC 95% CI P-value 
Platelet 0.76 0.57-0.94 0.020 
D.Bil/T.Bil ratio 0.83 0.66-0.99 0.003 
PT 0.80 0.64-0.97 0.006 
HGF 0.81 0.66-0.97 0.005 
PDGF-BB 0.83 0.69-0.98 0.003 
VEGF 0.77 0.60-0.94 0.015 
AUC, area under the curve; CI, confidence interval; D.Bil, direct birilubin; HGF, 
hepatocyte growth factor; PDGF, platelet-derived growth factor; PT, prothrombin; T.Bil, 
total bilirubin; VEGF, vascular endothelial growth factor.  
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Table 5. Associations between serum levels of angiogenic factors (HGF, PDGF-BB and 
VEGF) and laboratory data in 30 patients with FHF or AH. 
 HGF PDGF-BB VEGF 
HGF — -0.31 -0.29 
PDGF-BB — — 0.70** 
Platelet -0.26 0.79** 0.68** 
T.Bil 0.20 0.09 0.22 
D.Bil/T.Bil ratio -0.34 0.50** 0.35 
AST -0.11 -0.15 -0.39* 
ALT -0.08 -0.13 -0.26 
Cr 0.31 -0.10 -0.21 
PT activity -0.36 0.37* 0.38* 
Values shown the correlation coefficient (r) between the variables. 
*, P <0.05; P <0.01; Cr, creatinine; D.Bil, direct birilubin; HGF, hepatocyte growth 
factor; PDGF, platelet-derived growth factor; PT, prothrombin; T.Bil, total bilirubin; 
VEGF, vascular endothelial growth factor. 
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Figure Legends 
Figure 1. Serum HGF, PDGF-BB and VEGF levels of 30 patients with FHF or AH.  
A) Serum HGF levels were lower in patients with good outcomes than those with poor 
outcomes (including death and liver transplantation) (P = 0.004). B, C) Serum 
PDGF-BB and VEGF levels were higher in patients with good outcomes than those 
with poor outcomes (P = 0.002 and 0.010, respectively). 
